• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

    6/30/25 7:00:00 AM ET
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ONCY alert in real time by email

    SAN DIEGO and CALGARY, Alberta, June 30, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the appointment of Andrew Aromando as Chief Business Officer.

    Oncolytics Biotech® Inc. Logo (PRNewsfoto/Oncolytics Biotech® Inc.)

    Mr. Aromando most recently served as Chief Operating Officer at Ambrx Biopharma, where his contributions were instrumental in the $2 billion acquisition of the San Diego-based biotech by Johnson & Johnson. In his role at Oncolytics, Mr. Aromando will be responsible for leading global business development. He will also be directly involved with developing corporate, clinical and regulatory strategies. Among his key priorities will be optimizing the value of the Company's expansive suite of promising clinical data for pelareorep in multiple tumor types, including pancreatic, breast, and anal cancers.

    "Andrew's experience will be invaluable as we pursue aggressive clinical and business development strategies to maximize the value of pelareorep on an accelerated timeline," said Jared Kelly, Chief Executive Officer of Oncolytics. "He is a proven industry leader with a successful track record of navigating complex transactions and partnerships and an outstanding addition to our executive team."

    Mr. Aromando added, "I'm thrilled to join Oncolytics at such a pivotal moment in its evolution. With promising data in difficult-to-treat cancers and a compelling body of clinical evidence in over 1,100 patients, I believe the Company is uniquely positioned to deliver meaningful value to patients and other stakeholders in the near term."

    Mr. Aromando has over 30 years of experience in the life sciences industry. He has served more than 20 years in C-level positions at leading oncology-focused biopharma companies and global service providers. His senior executive roles at these companies were centered on strategic planning, corporate development, portfolio optimization, and product commercialization. He earned his BA from The College of New Jersey and MA from Rutgers University.

    As a material inducement to Mr. Aromando's appointment as Chief Business Officer, and in accordance with NASDAQ Listing Rule 5635(c)(4), Mr. Aromando has been awarded an initial stock option grant exercisable for 750,000 shares with an exercise price of CAD$0.93, vesting equally over three years with a term of 5 years from the date of grant. The Company also granted Mr. Aromando 500,000 restricted stock units, which vest upon the Company entering into a definitive agreement for certain transactions providing for the acquisition of the Company or the exclusive license of pelareorep.

    About Oncolytics Biotech Inc.

    Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.

    Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @oncolytics.

    This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic; our plans, objectives and strategies; our focus on advancing pelareorep into registration enabling studies; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. We may incur expenses or delays relating to events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

    Company Contact

    Jon Patton

    Director of IR & Communication

    [email protected]

    Investor Relations for Oncolytics

    Mike Moyer

    LifeSci Advisors

    +1-617-308-4306

    [email protected]

    Media Contact for Oncolytics

    Owen Blaschak

    LifeSci Communications

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/oncolytics-biotech-appoints-former-ambrx-executive-as-chief-business-officer-to-drive-business-development-strategy-302494308.html

    SOURCE Oncolytics Biotech® Inc.

    Get the next $ONCY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ONCY

    DatePrice TargetRatingAnalyst
    10/6/2022$3.00Buy
    Maxim Group
    More analyst ratings

    $ONCY
    SEC Filings

    See more
    • SEC Form 6-K filed by Oncolytics Biotech Inc.

      6-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)

      6/30/25 8:30:07 AM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Oncolytics Biotech Inc.

      6-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)

      6/11/25 7:32:53 AM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Oncolytics Biotech Inc.

      6-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)

      5/23/25 8:14:59 AM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONCY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Oncolytics Biotech with a new price target

      Maxim Group initiated coverage of Oncolytics Biotech with a rating of Buy and set a new price target of $3.00

      10/6/22 9:22:17 AM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Oncolytics Biotech with a new price target

      H.C. Wainwright initiated coverage of Oncolytics Biotech with a rating of Buy and set a new price target of $15.00

      2/17/21 2:20:07 PM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONCY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a

      6/30/25 11:02:00 AM ET
      $ARAY
      $CLRB
      $ERAS
      $INTS
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

      SAN DIEGO and CALGARY, Alberta, June 30, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the appointment of Andrew Aromando as Chief Business Officer. Mr. Aromando most recently served as Chief Operating Officer at Ambrx Biopharma, where his contributions were instrumental in the $2 billion acquisition of the San Diego-based biotech by Johnson & Johnson. In his role at Oncolytics, Mr. Aromando will be responsible for leading global business development. He will a

      6/30/25 7:00:00 AM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns 

      6/26/25 11:44:00 AM ET
      $ADCT
      $CTOR
      $ONCY
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONCY
    Leadership Updates

    Live Leadership Updates

    See more
    • Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a

      6/30/25 11:02:00 AM ET
      $ARAY
      $CLRB
      $ERAS
      $INTS
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

      SAN DIEGO and CALGARY, Alberta, June 30, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the appointment of Andrew Aromando as Chief Business Officer. Mr. Aromando most recently served as Chief Operating Officer at Ambrx Biopharma, where his contributions were instrumental in the $2 billion acquisition of the San Diego-based biotech by Johnson & Johnson. In his role at Oncolytics, Mr. Aromando will be responsible for leading global business development. He will a

      6/30/25 7:00:00 AM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns 

      6/26/25 11:44:00 AM ET
      $ADCT
      $CTOR
      $ONCY
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ONCY
    Financials

    Live finance-specific insights

    See more
    • Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

      American Society of Clinical Oncology (ASCO) GI Symposium data underscores pelareorep's clinical benefit in anal and pancreatic cancers Pelareorep featured in Key Opinion Leader event on oncolytic immunotherapies in breast and pancreatic cancers Poster on pelareorep's stimulation of adaptive and innate immunity to be shared at ASCO Annual Meeting Conference call and webcast today at 4:30 p.m. ET to discuss Q1 results and clinical outlook SAN DIEGO, Calif. and CALGARY, AB, May 14, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today reported on highlights and financial results for the first qu

      5/14/25 4:01:00 PM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

      Conference call and webcast to take place on Wednesday, May 14, 2025, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB, May 6, 2025 Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Wednesday, May 14, 2025, at 4:30 p.m. ET to discuss a corporate update and financial results for the first quarter of 2025. Conference Call & Webcast Date: Wednesday, May 14, 2025Time: 4:30 p.m. ETDial In – North American Toll-Free: (888) 510-2154Dial In – Interna

      5/6/25 7:00:00 AM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

      Conference call and webcast to take place on Friday, March 7, 2025, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB, Feb. 25, 2025 /CNW/ --  Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Friday, March 7, 2025, at 8:30 a.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2024. Conference Call & Webcast Date: Friday, March 7, 2025 Time: 8:30 a.m. ETDial In – North American Toll-Free: (888) 510-2154Dial In – International: (437) 900-0527RapidConnect: to join the conference call without operator assistance, plea

      2/25/25 12:43:00 PM ET
      $ONCY
      Biotechnology: Pharmaceutical Preparations
      Health Care